Variables |
Control group (n = 6) |
JIA group (n = 35) |
Biological therapy (n = 25) |
Non biological therapy (n = 10) |
---|---|---|---|---|
Female n (%) | 4 (66.6) | 23 (65.7) | 17 (68) | 6 (60) |
Age in y (IQR) | 11.6 (9.8-14.6) | 10.6 (8.8-12.7) | 11.4 (8.9-13.0) | 11.4 (4.7-12.3) |
Previous seasonal vaccination n (%) | 2 (33) | 22 (62.8) | 18 (72) | 4 (40) |
Duration of JIA in y (IQR) | 4.9 (2.7-8.3) | 5.99 (3.0-8.6) | 3.94 (2.5-4.7) | |
JIA category n (%) | ||||
Persistent oligoarthritis | 13 (37.1) | 7 (28) | 6 (60) | |
Extended oligoarthritis | 6 (17.1) | 5 (20) | 1 (10) | |
Polyarthritis RF negative | 6 (17.1) | 4 (16) | 2 (20) | |
Polyarthritis RF positive | 0 (0) | 0 (0) | 0 (0) | |
Systemic onset arthritis | 7 (20) | 7 (28) | 0 (0) | |
Enthesitis related arthritis | 3 (8.5) | 2 (8) | 1 (10) | |
Psoriatic arthritis | 0 | 0 | 0 | |
Undifferentiated arthritis | 0 | 0 | 0 | |
Treatment n (%) (a) | ||||
Without therapy | 3 (8.5) | _ | 3 (30) | |
Systemic corticosteroids (concomitant MTX + tocilizumab) | 2 (5.7) | 2 (8) | ||
Methotrexate monotherapy | 7 (20) | _ | 7 (70) | |
Biological monotherapy | 16 (45.7) | 16 (64) | _ | |
Biological therapy + methotrexate | 9 (25.7) | 9 (36) | _ | |
Duration of biological therapy in years (IQR) | NA | NA | 3.1 (1.8-4.8) | NA |
JADAS 71 (IQR) | 1 (0-5) | 3 (0-7) | 2 (0.25-6.75) | |
IgG mg/dl (IQR) | 1036 (888-1243) | 1021 (880-1249) | 1143 (965-1205) | |
Leukocytes ×109/L (IQR) | 6.5 (3.7-8.2) | 6.0 (5.2-7.4) | 5.8 (5.0-6.9) | 7.5 (5.9-9.1) |
Lymphocytes ×109/L | 2.3 (1.3-2.5) | 2.2 (1.6-2.8) | 2.2 (1.6-2.8) | 2.283 (1.9-3.1) |
Neutrophils ×109/L | 3.4 (2.0-4.7) | 3.1 (2.7-3.9) | 3.1 (2.5-3.6) | 3.9 (3.0-4.7) |
Hemoglobin g/L (IQR) | 13.3 (12.8-13.6) | 13.3 (12.7-13.6) | 13.3 (12.8-14.2) | 13.1 (12.2-13.3) |
Platelets ×109/L (IQR) | 305 (289-376) | 263 (234-320) | 255 (227-318) | 275 (251-356) |
ESR mm/h (IQR) | 5 (4.0-9.5) | 8 (4.0-10.5) | 6 (4.0-9.0) | 8.5 (6.5-10.8) |